Small Pharma has announced positive top-line findings from its Phase 2a clinical trial of SPL026 for the treatment of Major Depressive Disorder (MDD). SPL026 is an intravenous DMT (N,N-Dimethyltryptamine) formulation used in conjunction with supportive therapy.
The Phase 2a trial met its primary endpoint, revealing a statistically significant and clinically meaningful reduction in depressive symptoms two weeks after administration compared to a placebo. Moreover, key secondary endpoints indicated a rapid and enduring antidepressant effect lasting up to 12 weeks.
Dr. Carol Routledge, Chief Medical and Scientific Officer, expressed satisfaction with the trial results, emphasizing the significant antidepressant effect of SPL026 in combination with supportive therapy. The remission rate was reported to be 57% at three months following a single dose of SPL026. Additionally, the treatment exhibited a favorable safety and tolerability profile in MDD patients, consistent with the Phase 1 study.
The trial involved patients who had discontinued pharmacological antidepressant medication before dosing. Participants received a brief intravenous infusion of 21.5mg of SPL026, resulting in a 20 to 30-minute psychedelic experience. This dose was selected based on the Phase 1 study’s findings, which confirmed both its tolerability and the delivery of a consistent psychedelic experience in healthy volunteers.
Small Pharma CEO George Tziras expressed his delight with the top-line results, underlining their significance in addressing the unmet needs of millions of people worldwide affected by MDD. The company aims to develop short-duration psychedelics combined with supportive therapy as a treatment option for this condition.
Dr. David Erritzoe, Clinical Psychiatrist at Imperial College London and Chief Investigator of the Phase 1/2a study, noted the exciting prospects of SPL026 DMT as an effective treatment for individuals with MDD who experience limited benefits from existing antidepressants. He highlighted the potential for rapid and enduring relief from a single treatment, as demonstrated in the trial.
The detailed results of the Phase 2a trial are expected to be presented at scientific meetings and published in a peer-reviewed journal.
